The FRAME clinical trial (NCT01575834) was a phase 3 randomised, double-blind, placebo-controlled study, that investigated the efficacy and safety of romosozumab in postmenopausal women with osteoporosis (OP); the knee osteoarthritis (OA) substudy assessed the effect of treatment with romosozumab on the progression of OA of the knee in women with OP and knee OA. In this touchIMMUNOLOGY interview, we caught up with Dr. Nancy Lane (University of California Davis, Sacramento, CA, USA) to discuss the mechanism of action of romosozumab, the FRAME clinical trial, and the efficacy and safety findings of the knee OA substudy.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Effect of Romosozumab in Postmenopausal Women with Knee Osteoarthritis: Results from the FRAME Clinical Trial‘ (Abstract number: 1307) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- Could you tell us a little about the relationship between osteoporosis and osteoarthritis? (0:36)
- What is the mechanism of action of romosozumab? (1:50)
- Could you give us an overview of the FRAME clinical trial and the knee OA substudy? (2:45)
- What were the efficacy and safety findings of the substudy? (4:46)
Disclosures: Nancy Lane discloses consulting for Biosplice, receiving grant/research support from NIA, serving on advisory boards for Xalud and Genescense, and participating in speaker’s bureaus with Amgen.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
